Multiple Sclerosis and Menopause: the effect of hormone replacement therapy on clinical picture and immunology of multiple sclerosis

Irina Elovaara0 个研究点开始时间: 2014年12月12日最近更新: 2015年2月2日

适应症

试验速览

暂无简介。

•- Gender: female
•- Age 44-54 years
•- Peri- or postmenopausal
•- Course of diasease: relapsing-remitting
•- Multiple sclerosis is diagnosed with valid diagnostic criteria (valid at the time of the diagnosis)
•- Active disease (relapse or new T2- or Gd+ -lesion in MRI within a year)
•- EDSS max. 5.5
•- No estrogen/progestin or estrogen in use or two months wash-out period
•- No treatment or interferon beta, glatiramer acetate or teriflunomide for multiple sclerosis
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 40
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Course of disease: primary or secondary progressive multiple sclerosis or clinically isolated syndrome
•- EDSS more than 5.5
•- Use of estrogen/progestin or estrogen without two months wash-out period
•- Severe other health medical condition (e.g. malignancy, other autoimmune or neurodegenerative disease, severe psycholocigal disease)
•- Contraindication for hormone replacement therapy
•- Other immunomodulatory treatment than interferon beta, glatiramere acetate or teriflunomidi

发起方

Irina Elovaara